Patients with idiopathic pulmonary fibrosis may benefit from continued treatment with the anti-fibrotic pirfenidone even if their disease has progressed, new evidence suggests. The exploratory analysis involved 1247 patients with IPF from the CAPACITY and ASCEND phase III studies who were randomised to treatment with pirfenidone (Esbriet) or placebo. Results showed that patients with IPF ...
Already a member?
Enter your email to keep reading.